These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

707 related items for PubMed ID: 24072770

  • 21. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [Abstract] [Full Text] [Related]

  • 22. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr 11; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract] [Full Text] [Related]

  • 23. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ.
    Can J Cardiol; 2013 Jul 11; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [Abstract] [Full Text] [Related]

  • 24. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA, McMurtry MS.
    Can J Cardiol; 2013 Jul 11; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [Abstract] [Full Text] [Related]

  • 25. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY, Kim RB.
    Can J Cardiol; 2013 Jul 11; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [Abstract] [Full Text] [Related]

  • 26. Novel oral anticoagulants for stroke prevention in the geriatric population.
    Kim D, Barna R, Bridgeman MB, Brunetti L.
    Am J Cardiovasc Drugs; 2014 Feb 11; 14(1):15-29. PubMed ID: 24234513
    [Abstract] [Full Text] [Related]

  • 27. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation.
    Garcia DA.
    Thromb Res; 2012 Jan 11; 129(1):9-16. PubMed ID: 22018997
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Novel oral anticoagulants for stroke prevention in atrial fibrillation: key trial findings and clinical implications.
    Goette A.
    Trends Cardiovasc Med; 2013 May 11; 23(4):128-34. PubMed ID: 23313169
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.
    Anderson DR, Gardner MJ, Putnam W, Jassal D, Brownell B, Flowerdew G, Nagpal S, Thompson K, Cox JL.
    Can J Cardiol; 2005 Mar 11; 21(3):257-66. PubMed ID: 15776115
    [Abstract] [Full Text] [Related]

  • 36. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb 11; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF, Ganetsky V, Spinler SA.
    Clin Ther; 2013 Jan 11; 35(1):4-27. PubMed ID: 23328267
    [Abstract] [Full Text] [Related]

  • 39. [Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
    Tkacheva ON, Akasheva DU.
    Ter Arkh; 2014 Jan 11; 86(4):103-7. PubMed ID: 24864477
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.